business / news / / Benzinga
shares traded lower on Tuesday, tracking a broader market downturn.
Merck is acquiring Terns Pharmaceuticals for $53.00 per share in cash, with the offer expiring May 4, 2026.
KEY POINTS
- Merck's next financial update is scheduled for April 30, 2026, with an EPS estimate of -101 cents.
- Despite sector weakness, Merck has gained 44.67% over the last 12 months, nearing its 52-week high.
- JP Morgan recently raised Merck's price target to $135.00, reflecting continued analyst optimism.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →